Please assess the completion status of the following clinical trial:

Trial Title: Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Alcohol withdrawal syndrome (regardless of admitting diagnosis).~2. Severe symptoms, as defined by a 'Clinical Institute for Withdrawal Assessment Adult revised' (CIWA-Ar) score of 16 or more, or delirium severe enough to prohibit assessment with the CIWA-Ar, or observed withdrawal seizures, in each case despite treatment with at least 60 mg of diazepam (or an equivalent dose of another benzodiazepine) in the previous 16 hours, regardless of route of administration..~3. Early alcohol withdrawal, broadly defined as the first 16 hours after the diagnosis of acute alcohol withdrawal has been made. The time of diagnosis will be taken to be the time of prescription of symptom-triggered benzodiazepine therapy (CIWA protocol), or the time of consultation to ICU/Emergency Department, Internal Medicine, or the Addictions Service (Psychiatry) for the management of alcohol withdrawal.~4. Anticipated need for hospitalization (i.e. admission to ICU, medical step-up unit, or wards).~Exclusion Criteria:~1. an alternate etiology for delirium thought to be more likely than alcohol withdrawal;~2. age \<16 years;~3. pregnancy (positive assay for ßhCG). A urine assay or blood test will be performed for all women \< 55 yrs;~4. current breastfeeding;~5. severe acute hepatitis (AST or ALT \>500); liver failure (INR \>2 not otherwise explained);~6. a presenting complaint of neurotrauma, brain mass, or intra-cranial bleed; abnormal cell count or gram stain on lumbar puncture (if performed);~7. strong clinical suspicion of recent co-ingestion of depressant drugs (e.g. opioids, toxic alcohols, gamma-hydroxy-butyrate);~8. hemodynamic instability (systolic blood pressure \[SBP\] \< 90 mmHg);~9. history of barbiturate allergy;~10. history of porphyria;~11. history of myasthenia gravis;~12. inability to obtain IV access;~13. anticipated transfer to another centre;~14. stated intent to leave against medical advice;~15. active outpatient prescription for anti-retroviral therapy for HIV~16. active outpatient prescription for one of the following anti-epileptic drugs: valproic acid, phenytoin, carbamazepine, clobazam, lacosamide, lamotrigine, levetiracetam, topiramate, primidone, or phenobarbital.~17. active outpatient prescription for an anticoagulant medication with a significant metabolic interaction with phenobarbital (i.e. warfarin or apixaban).~18. active outpatient prescription for a monoamine oxidase inhibitor (e.g., phenelzine, selegiline, tranylcypromine, isocarboxazid)~19. renal failure, as defined by a creatinine clearance \<10 mls/minute (as calculated by Cockcroft-Gault equation) and/or active receipt of renal replacement therapy (dialysis).~20. administration of IV or oral phenobarbital during the index admission prior to randomization.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phenobarbital (Type: EXPERIMENTAL): Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive an inactive placebo (IV).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues